Cargando…

Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone

OBJECTIVE: To compare the impact on thrombin generation of the new combined oral contraceptive containing 15 mg estetrol and 3 mg drospirenone with ethinylestradiol (30 or 20 mcg) associated either with 150 mcg levonorgestrel or with 3 mg drospirenone. METHODS: Data were collected from the “E4/DRSP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morimont, Laure, Jost, Maud, Gaspard, Ulysse, Foidart, Jean-Michel, Dogné, Jean-Michel, Douxfils, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759169/ https://www.ncbi.nlm.nih.gov/pubmed/36099501 http://dx.doi.org/10.1210/clinem/dgac511

Ejemplares similares

The benefits of estetrol addition to drospirenone for contraception
por: Foidart, Jean Michel, et al.
Publicado: (2023)

An Oral Contraceptive Containing Estetrol 15 MG and Drospirenone 3 MG Has Limited Effects on Endocrine and Metabolic Parameters
por: Klipping, Christine, et al.
Publicado: (2021)

Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
por: Morimont, Laure, et al.
Publicado: (2021)

The Effect of Estetrol/Drospirenone on Ovarian Function Is Similar to a Well-Established Combined Oral Contraceptive: Results From a Phase 2 Study
por: Duijkers, Ingrid J M, et al.
Publicado: (2021)

RF34 | PMON202 The Human Metabolic Profile of Estetrol
por: Gérard, Céline, et al.
Publicado: (2022)

Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Analytical performance of the endogenous thrombin potential–based activated protein C resistance assay on the automated ST Genesia system
por: Morimont, Laure, et al.
Publicado: (2022)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy
por: Douxfils, Jonathan, et al.
Publicado: (2023)

Estetrol‐Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia
por: Gemzell‐Danielsson, K, et al.
Publicado: (2021)

Hormonal therapies and venous thrombosis: Estrogen matters!
por: Morimont, Laure, et al.
Publicado: (2023)

Hormonal therapies and venous thrombosis: considerations for prevention and management—a reappraisal
por: Douxfils, Jonathan, et al.
Publicado: (2023)

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study
por: Duijkers, Ingrid J.M., et al.
Publicado: (2015)

A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life
por: Gaspard, Ulysse, et al.
Publicado: (2023)

A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety
por: Gaspard, Ulysse, et al.
Publicado: (2020)

Estetrol and Mammary Gland: Friends or Foes?
por: Gallez, Anne, et al.
Publicado: (2021)

Estetrol: From Preclinical to Clinical Pharmacology and Advances in the Understanding of the Molecular Mechanism of Action
por: Gérard, Céline, et al.
Publicado: (2023)

Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer
por: Gallez, Anne, et al.
Publicado: (2021)

Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives
por: Mawet, Marie, et al.
Publicado: (2015)

SUN-LB001 Estetrol (E4) Is a Unique Estrogen with Selective Actions in Tissues Which Are Distinctly Different from the Actions of SERMs
por: Foidart, Jean-Michel, et al.
Publicado: (2019)

Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study
por: Foidart, Jean Michel, et al.
Publicado: (2023)

Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study
por: Tskitishvili, Ekaterine, et al.
Publicado: (2016)

Estetrol: A New Choice for Contraception
por: Fruzzetti, Franca, et al.
Publicado: (2021)

Use of estetrol with other steroids for attenuation of neonatal hypoxic-Ischemic brain injury: to combine or not to combine?
por: Tskitishvili, Ekaterine, et al.
Publicado: (2016)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
por: Madigan, David, et al.
Publicado: (2018)

Interlaboratory variability of activated protein C resistance using the ETP‐based APC resistance assay
por: Morimont, Laure, et al.
Publicado: (2021)

Comparison of Estetrol Exposure between Women and Mice to Model Preclinical Experiments and Anticipate Human Treatment
por: Gallez, Anne, et al.
Publicado: (2023)

Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms
por: Gérard, Céline, et al.
Publicado: (2015)

Vitamin D serum levels in women using contraception containing drospirenone – a preliminary study
por: Ciebiera, Michał, et al.
Publicado: (2017)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles
por: Gheldof, Damien, et al.
Publicado: (2013)

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
por: Wichianpitaya, Jirath, et al.
Publicado: (2013)

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015)

Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database
por: Parkin, Lianne, et al.
Publicado: (2011)

Preparation and Evaluation of Intravaginal Ring Containing Drospirenone
por: Zhang, Ying, et al.
Publicado: (2013)

Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone)
por: Podfigurna, A., et al.
Publicado: (2019)

Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
por: Tan, Jerry KL, et al.
Publicado: (2010)

Head-to-Head Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-CoV-2 Infection
por: Favresse, Julien, et al.
Publicado: (2021)

Drospirenone and mood
por: Zuschmann, Andrew
Publicado: (2022)

Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview
por: Archer, David F., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1ff5q6q4o92c4gi7fq6bqa2gir